天堂网亚洲,天天操天天搞,91视频高清,菠萝蜜视频在线观看入口,美女视频性感美女视频,95丝袜美女视频国产,超高清美女视频图片

Home Cart 0 Sign in  

[ CAS No. 1533519-92-4 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
Chemical Structure| 1533519-92-4
Chemical Structure| 1533519-92-4
Structure of 1533519-92-4 * Storage: {[proInfo.prStorage]}

Please Login or Create an Account to: See VIP prices and availability

Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Search after Editing

* Storage: {[proInfo.prStorage]}

* Shipping: {[proInfo.prShipping]}

Quality Control of [ 1533519-92-4 ]

Related Doc. of [ 1533519-92-4 ]

Alternatived Products of [ 1533519-92-4 ]
Product Citations

Product Details of [ 1533519-92-4 ]

CAS No. :1533519-92-4 MDL No. :MFCD28387394
Formula : C13H14ClN Boiling Point : -
Linear Structure Formula :- InChI Key :CIQWZUGROQAMOL-UHFFFAOYSA-N
M.W : 219.71 Pubchem ID :91827884
Synonyms :

Calculated chemistry of [ 1533519-92-4 ]      Expand+

Physicochemical Properties

Num. heavy atoms : 15
Num. arom. heavy atoms : 10
Fraction Csp3 : 0.23
Num. rotatable bonds : 1
Num. H-bond acceptors : 0.0
Num. H-bond donors : 1.0
Molar Refractivity : 67.78
TPSA : 26.02 ?2

Pharmacokinetics

GI absorption : High
BBB permeant : Yes
P-gp substrate : Yes
CYP1A2 inhibitor : Yes
CYP2C19 inhibitor : No
CYP2C9 inhibitor : No
CYP2D6 inhibitor : No
CYP3A4 inhibitor : Yes
Log Kp (skin permeation) : -4.66 cm/s

Lipophilicity

Log Po/w (iLOGP) : 0.0
Log Po/w (XLOGP3) : 4.2
Log Po/w (WLOGP) : 4.05
Log Po/w (MLOGP) : 3.26
Log Po/w (SILICOS-IT) : 3.27
Consensus Log Po/w : 2.95

Druglikeness

Lipinski : 0.0
Ghose : None
Veber : 0.0
Egan : 0.0
Muegge : 1.0
Bioavailability Score : 0.55

Water Solubility

Log S (ESOL) : -4.28
Solubility : 0.0116 mg/ml ; 0.000053 mol/l
Class : Moderately soluble
Log S (Ali) : -4.46
Solubility : 0.00769 mg/ml ; 0.000035 mol/l
Class : Moderately soluble
Log S (SILICOS-IT) : -4.31
Solubility : 0.0107 mg/ml ; 0.0000486 mol/l
Class : Moderately soluble

Medicinal Chemistry

PAINS : 0.0 alert
Brenk : 1.0 alert
Leadlikeness : 2.0
Synthetic accessibility : 1.11

Safety of [ 1533519-92-4 ]

Signal Word:Warning Class:N/A
Precautionary Statements:P261-P305+P351+P338 UN#:N/A
Hazard Statements:H302-H315-H319-H335 Packing Group:N/A
GHS Pictogram:

Application In Synthesis of [ 1533519-92-4 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Downstream synthetic route of [ 1533519-92-4 ]

[ 1533519-92-4 ] Synthesis Path-Downstream   1~12

  • 1
  • [ 90-11-9 ]
  • [ 1533519-92-4 ]
  • 2
  • [ 878671-93-3 ]
  • [ 1533519-92-4 ]
YieldReaction ConditionsOperation in experiment
[0349] Cyclopropylmagnesium bromide was added to a solution of bromonaphthalene in tetrahydrofuran stirred at 0-5 C in the presence of catalytic amount of [1,3- bis(diphenylphosphino)propane]dichloronickel(II) to form cyclopropylnaphthalene, which was diluted with ethyl acetate and washed. [0350] Cyclopropylnaphthalene (Compound 6) was dissolved in dichloromethane, then nitric acid was added at 0 C and the reaction mixture was allowed to warm to ambient temperature. After reaction completion, the mixture was neutralized with sodium bicarbonate then washed with water, and l-cyclopropyl-4-nitronaphthalene (Compound 7) was used in the next step without further purification. [0351] Compound 7 was dissolved in methanol, and hydrogenated with hydrazine hydrate at reflux temperature. The crude l-amino-4-cyclopropylnaphthalene (Compound 8) was dissolved in ethanol and reacted with di-tert-butyl dicarbonate in the presence of triethylamine to give tert- butyl 4-cyclopropylnaphthalen-l-ylcarbamate (Compound 14)which was precipitated from methyl tert-butyl ketone. [0352] The protecting group in Compound 14 was removed by hydrochloric acid in ethanol to afford amino-4-cyclopropylnaphthalene which crystallized as an hydrochloride salt (compound 8-B). [0353] 4-Cyclopropylnaphthalen-l -amine hydrochloride (Compound 8-B) was dissolved in dichloromethane and treated with thiophosgene in the presence of sodium hydroxide to generate the corresponding isothiocyanate intermediate COmpound 9. [0354] l-Cyclopropyl-4-isothiocyanatonaphthalene was solvent exchanged with DMF and condensed with amino guanidine hydrochloride to generate the corresponding substituted thiosemicarbazide (Compound 13). Compound 13 was heated in the presence of aqueous sodium hydroxide to form Compound 11 , which was purified by crystallization from a mixture of ethanol and water, then recrystallized from a mixture of dimethylformamide and water. [0355] While preferred embodiments of the present invention have been shown and described herein, it will be obvious to those skilled in the art that such embodiments are provided by way of example only. Numerous variations, changes, and substitutions will now occur to those skilled in the art without departing from the invention. It should be understood that various alternatives to the embodiments of the invention described herein may be employed in practicing the invention. It is intended that the following claims define the scope of the invention and that methods and structures within the scope of these claims and their equivalents be covered thereby.
  • 3
  • [ 463-71-8 ]
  • [ 1533519-92-4 ]
  • [ 878671-95-5 ]
YieldReaction ConditionsOperation in experiment
With potassium hydroxide; In dichloromethane; [0349] Cyclopropylmagnesium bromide was added to a solution of bromonaphthalene in tetrahydrofuran stirred at 0-5 C in the presence of catalytic amount of [1,3- bis(diphenylphosphino)propane]dichloronickel(II) to form cyclopropylnaphthalene, which was diluted with ethyl acetate and washed. [0350] Cyclopropylnaphthalene (Compound 6) was dissolved in dichloromethane, then nitric acid was added at 0 C and the reaction mixture was allowed to warm to ambient temperature. After reaction completion, the mixture was neutralized with sodium bicarbonate then washed with water, and l-cyclopropyl-4-nitronaphthalene (Compound 7) was used in the next step without further purification. [0351] Compound 7 was dissolved in methanol, and hydrogenated with hydrazine hydrate at reflux temperature. The crude l-amino-4-cyclopropylnaphthalene (Compound 8) was dissolved in ethanol and reacted with di-tert-butyl dicarbonate in the presence of triethylamine to give tert- butyl 4-cyclopropylnaphthalen-l-ylcarbamate (Compound 14)which was precipitated from methyl tert-butyl ketone. [0352] The protecting group in Compound 14 was removed by hydrochloric acid in ethanol to afford amino-4-cyclopropylnaphthalene which crystallized as an hydrochloride salt (compound 8-B). [0353] 4-Cyclopropylnaphthalen-l -amine hydrochloride (Compound 8-B) was dissolved in dichloromethane and treated with thiophosgene in the presence of sodium hydroxide to generate the corresponding isothiocyanate intermediate COmpound 9. [0354] l-Cyclopropyl-4-isothiocyanatonaphthalene was solvent exchanged with DMF and condensed with amino guanidine hydrochloride to generate the corresponding substituted thiosemicarbazide (Compound 13). Compound 13 was heated in the presence of aqueous sodium hydroxide to form Compound 11 , which was purified by crystallization from a mixture of ethanol and water, then recrystallized from a mixture of dimethylformamide and water. [0355] While preferred embodiments of the present invention have been shown and described herein, it will be obvious to those skilled in the art that such embodiments are provided by way of example only. Numerous variations, changes, and substitutions will now occur to those skilled in the art without departing from the invention. It should be understood that various alternatives to the embodiments of the invention described herein may be employed in practicing the invention. It is intended that the following claims define the scope of the invention and that methods and structures within the scope of these claims and their equivalents be covered thereby.
  • 4
  • [ 1533519-92-4 ]
  • 2-(5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-ylthio)acetic acid methyl ester [ No CAS ]
  • 5
  • [ 1533519-92-4 ]
  • [ 878671-96-6 ]
  • 6
  • [ 1533519-92-4 ]
  • 2-((5-amino-4-(4-cyclopropyl-naphthalen-1-yl)-4H-1,2,4-triazol-3-yl)thio)acetic acid methyl ester [ No CAS ]
  • 7
  • [ 1533519-92-4 ]
  • 2-[5-bromo-4-(4-cyclopropylnaphthalen-1-yl)-4H-1,2,4-triazol-3-yl]sulfanyl}acetic acid [ No CAS ]
  • 8
  • [ 1533519-92-4 ]
  • [ 1533519-90-2 ]
  • 9
  • [ 1533519-92-4 ]
  • [ 1533519-86-6 ]
  • 10
  • [ 1533519-92-4 ]
  • [ 1533519-84-4 ]
  • 11
  • [ 1533519-92-4 ]
  • [ 1151516-14-1 ]
  • 12
  • [ 1533519-92-4 ]
  • [ 1533519-85-5 ]
Recommend Products
Same Skeleton Products

Technical Information

Historical Records

Related Functional Groups of
[ 1533519-92-4 ]

Aryls

Chemical Structure| 878671-94-4

[ 878671-94-4 ]

4-Cyclopropylnaphthalen-1-amine

Similarity: 0.97

Chemical Structure| 1588440-94-1

[ 1588440-94-1 ]

4-Cyclopropylaniline hydrochloride

Similarity: 0.89

Chemical Structure| 1416354-38-5

[ 1416354-38-5 ]

4-(2-Phenylpropan-2-yl)aniline hydrochloride

Similarity: 0.86

Chemical Structure| 485402-64-0

[ 485402-64-0 ]

3-Cyclopropylaniline

Similarity: 0.86

Chemical Structure| 130523-30-7

[ 130523-30-7 ]

8-Methylnaphthalen-1-amine

Similarity: 0.86

Amines

Chemical Structure| 878671-94-4

[ 878671-94-4 ]

4-Cyclopropylnaphthalen-1-amine

Similarity: 0.97

Chemical Structure| 1588440-94-1

[ 1588440-94-1 ]

4-Cyclopropylaniline hydrochloride

Similarity: 0.89

Chemical Structure| 1416354-38-5

[ 1416354-38-5 ]

4-(2-Phenylpropan-2-yl)aniline hydrochloride

Similarity: 0.86

Chemical Structure| 485402-64-0

[ 485402-64-0 ]

3-Cyclopropylaniline

Similarity: 0.86

Chemical Structure| 130523-30-7

[ 130523-30-7 ]

8-Methylnaphthalen-1-amine

Similarity: 0.86

; ;